No, there is no generic version of Linzess (linaclotide) available in the United States. The brand-name drug remains the only option on the market, with a retail price around $282 per month. Patent protections block generic competition until at least 2031, though one generic manufacturer has already received tentative FDA approval and is waiting in the wings.
Why No Generic Exists Yet
Linzess is protected by patents that prevent other companies from selling copies of the drug. The key patents covering the 145 mcg and 290 mcg capsules don’t expire until October 30, 2031. The patent on the 72 mcg capsule extends even further, to August 16, 2033. Until these dates pass, or unless a court invalidates the patents earlier, no generic can reach pharmacy shelves.
That said, the groundwork for a generic is already being laid. Teva Pharmaceuticals received tentative FDA approval for a generic version of the 72 mcg capsule. “Tentative approval” means the FDA has reviewed the product, confirmed it is bioequivalent to brand-name Linzess, and judged it safe and effective. The only thing blocking a full green light is the existing patent. Once patent exclusivity ends, Teva and potentially other manufacturers could launch their generics relatively quickly.
What Linzess Treats
Linzess is FDA-approved for three conditions. In adults, it treats irritable bowel syndrome with constipation (IBS-C) at the 290 mcg dose and chronic idiopathic constipation (CIC) at the 145 mcg dose, with the option to drop to 72 mcg if needed for tolerability. It’s also approved for functional constipation in children ages 6 and older at 72 mcg, and for IBS-C in children 7 and older at 145 mcg.
The drug works by triggering receptors on the inner lining of your intestines. When it binds to those receptors, it sets off a chain reaction that pushes chloride and bicarbonate ions into the intestinal space. Water follows the ions, softening stool and speeding up transit. The same signaling pathway also reduces the activity of pain-sensing nerves in the gut wall, which is part of why it helps with the abdominal pain that comes with IBS-C, not just the constipation itself.
Cost Without a Generic
At roughly $282 per month retail, Linzess is expensive for an ongoing daily medication, especially for people without insurance or whose plan places it on a high copay tier. Some insurance formularies classify it as non-preferred or non-formulary, meaning you may need prior authorization before your plan will cover it. The VA system, for example, lists linaclotide as non-formulary and requires a special approval process.
Without a generic alternative to drive prices down, your main options for reducing cost are manufacturer savings programs, pharmacy discount cards, or working with your prescriber to submit a prior authorization if your insurer initially denies coverage. Some patients also find that the 72 mcg dose, if clinically appropriate, can be slightly less expensive than the higher strengths depending on pharmacy pricing.
Side Effects to Know About
Diarrhea is the most common side effect, which makes sense given that the drug works by pulling water into your intestines. In a large pediatric clinical trial, about 4% of patients on linaclotide experienced diarrhea compared to 2% on placebo. Adult rates tend to be higher, particularly at the 290 mcg dose used for IBS-C. Most cases are mild to moderate, but severe diarrhea leading to dehydration is possible. In the pediatric trial, one patient was hospitalized for dehydration from severe diarrhea but recovered fully after receiving fluids.
Taking Linzess on an empty stomach at least 30 minutes before your first meal of the day helps with consistent absorption and can reduce the likelihood of digestive side effects.
What to Do in the Meantime
If cost is the primary barrier, ask your prescriber about other medications in the same therapeutic space that may already have generics or lower price points. Lubiprostone, for instance, is another prescription option for CIC and IBS-C that has been on the market longer, though it works through a different mechanism and has its own side effect profile.
For those who respond well to Linzess and want to keep taking it, the brand manufacturer periodically offers copay assistance programs that can bring out-of-pocket costs down significantly for commercially insured patients. These programs typically don’t apply to government insurance like Medicare or Medicaid. Checking the manufacturer’s website or asking your pharmacy about current offers is the most direct way to find savings until generics eventually become available after 2031.